Fredun Pharmaceuticals, a diversified Indian pharma formulation company, has delivered a sharp performance in FY26, reporting strong growth in revenue, profitability, and margins.
For the year, the company posted a standout set of numbers: revenue surged to Rs. 639 crore, up 40% year-on-year, driven by sustained demand across key segments. EBITDA jumped 72% YoY to ~Rs. 95 crore, with margins expanding to 14.8%, underscoring improved operating efficiency. Net profit (PAT) rose ~60% YoY to Rs. 33 crore, outpacing revenue growth and highlighting strengthening business quality.
Momentum remained strong in the final quarter as well, with Q4 EBITDA rising 67% YoY and PAT climbing 56% YoY. The company said profitability is now growing faster than revenue, supported by operating leverage and tighter cost control. Improved financial ratios and steady cash flow generation further reinforced its balance sheet strength.
The Board has recommended a dividend of Rs. 0.70 per share and also proposed a bonus issue in the ratio of 2:1—offering two fully paid-up equity shares of Rs. 10 each for every one existing share of Rs. 10 each, subject to shareholder approval and record date eligibility.
Commenting on the financial performance Fredun Medhora, Managing Director, said, "FY26 reflects the steady progress we have made in building a diversified and resilient business. Our growth is coming across segments, with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals, and pet care.
"This balanced mix is helping us scale more sustainably and reduce dependence on any single segment. The improvement is clearly visible in our performance, with revenue reaching Rs. 639 crore and margins strengthening during the year.
"At the same time, we have started investing in the next phase of growth. The launch of our premium hormone therapy range and the DAULCÉL platform marks our entry into more specialized, wellness and preventive healthcare segments."
He added: "These are early steps, but they open up new avenues beyond our traditional business. Alongside this, the expansion of our Palghar facility and the upgrade in our credit rating to IVR BBB+ give us the capacity and financial strength to support future growth.
"Going forward, our focus will be on continuing to build across segments while gradually increasing the share of differentiated and higher value products. With multiple growth drivers now in place and a stronger base established, we are confident of sustaining this momentum and delivering consistent growth in the years ahead."
